ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, today announced that it has acquired Respicardia, Inc., a provider of novel implantable neurostimulators for the treatment of moderate to severe Central Sleep Apnea (CSA). CSA is a serious condition that is often associated with heart failure, coronary artery disease, and certain cardiac arrhythmias. Respicardia’s remedē® System is a revolutionary treatment for CSA, and is the only implantable device approved by the U.S. Food and Drug Administration (FDA) to treat moderate to severe CSA in adult patients with reduced cardiac function.
Read the full article: ZOLL Medical Corporation Acquires Respicardia, Inc. //
Source: https://www.businesswire.com/news/home/20210412005202/en/ZOLL-Medical-Corporation-Acquires-Respicardia-Inc.